Table 4

Meibomian gland parameters in healthy controls and glaucoma groups

GroupCell density of eyelid margin, cells/mm2Acinar unit
Superficial epitheliumBasal epitheliumArea, µm2±SDDensity, units/mm2Secretion reflectivityGlandular orifice area, µm2±SDMG wall: inhomogeneous appearance of MG wallPeriglandular interstice: inhomogeneous appearance of MG interstice
Controls1810.27±234.19*4066.94±284.54*,**17020.49±7284.38**219.31±50.62**1.12±0.22**1894.44±336.65**1.33±0.37***1.11±0.25***
Group 11789.70±208.763930.64±264.0**16787.89±6311.04195.33±58.551.23±0.30****1847.66±818.42**1.63±0.50****1.65±0.64****
 PF drugs1863.66±156.934030.83±121.6617742.75±5131.74222.40±45.251.08±0.131956.32±855.781.27±0.42*****1.31±0.32*****
 Preserved drugs1752.84±157.073867.36±310.2014953.24±6792.05******174.98±59.53******1.32±0.351779.03±809.911.85±0.42******1.86±0.71******
Group 21427.5±203.463548.58±467.0812208.10±2771.18100.47±33.232.49±0.462413.70±621.692.66±0.601.95±0.69
Group 31380.46±169.443439.69±366.2511652.55±2891.86102.17±40.892.87±0.612332.03±339.773.17±0.532.73±0.66
  • *p<0.001 vs group 2; p<0.05 vs group 1, preserved drugs.

  • **p<0.05 vs groups 2 and 3; p<0.001 for secretion reflectivity.

  • ***p<0.05 vs groups 1, 2 and 3.

  • ****p<0.05 vs groups 2 and 3.

  • *****p<0.05 vs preserved drugs.

  • ******p<0.05 vs groups 2 and 3.

  • MG, Meibomian gland; PF, preservative free.